Biocon, Mylan launch Fulphila in Australia

14 Apr 2020 Evaluate

Biocon and Mylan N.V. have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim) in Australia. Fulphila is approved by the Therapeutic Goods Administration for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infections, as manifested by febrile neutropenia. Fulphila is now available on the Pharmaceutical Benefits Scheme (PBS).

The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data, which confirmed that the product is highly similar to Neulasta and no clinically meaningful differences in terms of safety and efficacy exist.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

368.45 3.20 (0.88%)
28-Jan-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1616.15
Dr. Reddys Lab 1220.30
Cipla 1315.70
Zydus Lifesciences 891.85
Lupin 2118.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×